Evidence map›Paper›PMID 39682120›Full record

ArticleCancers2024

Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.

Elisabetta Xue, Dara Bracken-Clarke, Harris Krause, Tolulope Adeyelu, Mark G Evans, Dilara Akbulut, Martha Quezado, Nishant Gandhi, Alex Farrell, Heloisa P Soares and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Elisabetta XueCenter for Immuno-Oncology, National Cancer Institute, National Institute of Health, Bethesda, MD 20894, USA.
Dara Bracken-ClarkeCenter for Immuno-Oncology, National Cancer Institute, National Institute of Health, Bethesda, MD 20894, USA.ORCID 0000-0002-1105-1079
Harris KrauseCARIS Life Sciences, Phoenix, AZ 85040, USA.
Tolulope AdeyeluCARIS Life Sciences, Phoenix, AZ 85040, USA.
Mark G EvansCARIS Life Sciences, Phoenix, AZ 85040, USA.ORCID 0000-0001-9358-9843
Dilara AkbulutLaboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD 20894, USA.ORCID 0000-0003-2288-9667
Martha QuezadoLaboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD 20894, USA.
Nishant GandhiCARIS Life Sciences, Phoenix, AZ 85040, USA.
Alex FarrellCARIS Life Sciences, Phoenix, AZ 85040, USA.
Heloisa P SoaresHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0002-5185-2583
Emil LouDepartment of Medicine, Division of Hematology Oncology and Transplant, University of Minnesota, Minneapolis, MN 55414, USA.ORCID 0000-0002-1607-1386
Minh PhanStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.
Rusha PatelStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.
Ari M VanderwaldeCARIS Life Sciences, Phoenix, AZ 85040, USA.
Andrew ElliottCARIS Life Sciences, Phoenix, AZ 85040, USA.ORCID 0000-0001-8494-8031
Conor E SteuerDepartment of Hematology-Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30308, USA.
Nabil F SabaDepartment of Hematology-Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30308, USA.ORCID 0000-0003-4972-1477
Daniel J LubinDepartment of Hematology-Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30308, USA.
Nyall R LondonDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.ORCID 0000-0002-2902-4407
James L GulleyCenter for Immuno-Oncology, National Cancer Institute, National Institute of Health, Bethesda, MD 20894, USA.
Charalampos S FloudasCenter for Immuno-Oncology, National Cancer Institute, National Institute of Health, Bethesda, MD 20894, USA.ORCID 0000-0002-0020-237X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olfactory neuroblastoma (ONB), sinonasal undifferentiated carcinoma (SNUC), and sinonasal neuroendocrine carcinoma (SNEC) are rare malignancies arising from the sinonasal tract with limited therapeutic options. The expression of the somatostatin receptor 2 gene (

Indexed as

exome sequencingolfactory neuroblastomaRNA-Seqsinonasal neuroendocrine carcinomasinonasal undifferentiated carcinomasomatostatin receptor 2tumor biomarkerstumor microenvironment

Identifiers

PMID39682120
PMCPMC11640466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.